Your browser doesn't support javascript.
loading
The Effectiveness of a Dietary Supplement with Honey, Propolis, Pelargonium sidoides Extract, and Zinc in Children Affected by Acute Tonsillopharyngitis: An Open, Randomized, and Controlled Trial.
Cardinale, Fabio; Barattini, Dionisio Franco; Martinucci, Valentina; Bordea, Maria Morariu; Barattini, Luca; Rosu, Serban.
Afiliación
  • Cardinale F; Complex Operating Unit Paediatrics, Giovanni XXIII Paediatric Hospital, University of Bari, 70124 Bari, Italy.
  • Barattini DF; Opera Contract Research Organization, Tigermed Company, 300209 Timisoara, Romania.
  • Martinucci V; Pediatrica S.r.l., 57121 Livorno, Italy.
  • Bordea MM; Cabinet Medical Medicina de Familie Dr Morariu Bordea, 300425 Timisoara, Romania.
  • Barattini L; Tigermed Italy S.r.l., 16129 Genova, Italy.
  • Rosu S; Department of Oral and Cranio-Maxillo-Facial Surgery, University of Medicine and Pharmacy Victor Babes, 300041 Timisoara, Romania.
Pharmaceuticals (Basel) ; 17(6)2024 Jun 19.
Article en En | MEDLINE | ID: mdl-38931472
ABSTRACT
Physicians are currently finding products for pediatric respiratory diseases of viral etiology to reduce the inappropriate use of antibiotic therapy. This study evaluated PediaFlù (Pediatrica S.r.l.), a dietary supplement already on the market composed of honey, propolis, Pelargonium sidoides extract, and zinc (DSHPP), in children affected by acute tonsillopharyngitis (ATR). The open-label, randomized, and controlled study compared DSHPP + standard of care (SoC) versus SoC alone for six days. Children between 3 and 10 years with an ATR ≤ 48 h, a negative rapid test for beta-hemolytic Streptococcus, or a culture identification of nasal and/or pharyngeal exudates were included. A tonsillitis severity score (TSS) and the number of treatment failures (using ibuprofen or high-dose paracetamol as rescue medication) were the primary endpoints. DSHPP+ SoC showed better performance than SoC alone for TSS sub-scores throat pain and erythema on day 6 (p < 0.001 and p < 0.05), swallowing (p < 0.01 on day 4), and TSS total score on days 4 and 6 (p < 0.05 and p < 0.001). Only one patient (SoC group) had treatment failure for ibuprofen administration. No adverse events were reported. DSHPP is an optimal adjuvant in the treatment of URTI and could potentially be useful in the daily clinical practice of paediatricians evaluating the correct antibiotic prescription.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Pharmaceuticals (Basel) Año: 2024 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Suiza

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Pharmaceuticals (Basel) Año: 2024 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Suiza